Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
NCT06022822Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate adenocarcinoma comparing Arm I (urolithin A) with Arm II (placebo) (2 arms). Primary endpoint: Percent positive change in 8-OHdG. Started Sep 2024; status: recruiting.
02
Drugs
Urolithin A
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06022822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022822.